Zepose Plus (irbesartan + hydrochlorothiazide): Uses, Dosage & Side Effects

What it's for (Indications)

Irbesartan + Hydrochlorothiazide is primarily indicated for the treatment of essential hypertension in adults.
This fixed-dose combination therapy is particularly useful for patients whose blood pressure is not adequately controlled with irbesartan or hydrochlorothiazide monotherapy, or for whom the benefits of combination therapy outweigh the risks as an initial treatment.
The synergistic action of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide) provides effective blood pressure reduction, thereby mitigating the long-term risks associated with uncontrolled hypertension, such as stroke, myocardial infarction, and kidney disease.
Its use helps achieve target blood pressure goals more efficiently in suitable patient populations, often simplifying medication regimens.
This combination is a cornerstone in managing moderate to severe hypertension, where dual-agent therapy is often required to achieve optimal therapeutic outcomes and reduce cardiovascular morbidity and mortality.

Dosage Information

Type	Guideline
Standard	Specific dosage guidelines are not provided in the available data. Dosage should be individualized based on patient response and clinical assessment by a healthcare professional.

Safety & Warnings

Common Side Effects

The combination of irbesartan and hydrochlorothiazide can lead to various side effects, reflecting the pharmacological actions of both components.
Common side effects may include dizziness, fatigue, nausea, muscle pain (myalgia), and headache.
Due to the diuretic component, electrolyte imbalances such as hypokalemia (low potassium), hyponatremia (low sodium), hypomagnesemia (low magnesium), and hypercalcemia (high calcium) can occur, necessitating regular monitoring.
Hyperuricemia (elevated uric acid) leading to gout attacks is also a potential concern.
Less common but more serious adverse reactions can involve orthostatic hypotension, renal dysfunction (especially in patients with pre-existing kidney impairment or volume depletion), severe allergic reactions (angioedema), and hepatic impairment.
Photosensitivity, pancreatitis, and hematologic abnormalities (e.
g.
, thrombocytopenia) are rare but reported.
Patients should be advised to report any persistent or severe symptoms to their healthcare provider for evaluation and management, as some effects may require immediate medical attention or dosage adjustment to prevent further complications.

Serious Warnings

Black Box Warning: The combination product containing irbesartan and hydrochlorothiazide carries a significant Black Box Warning concerning fetal toxicity. Drugs that act directly on the renin-angiotensin system (RAS), including irbesartan, can cause injury and death to the developing fetus when administered to pregnant women. Exposure to these agents during the second and third trimesters of pregnancy is known to cause severe fetal toxicity, including hypotension, renal failure, hyperkalemia, and oligohydramnios. Oligohydramnios, in turn, can be associated with fetal lung hypoplasia and skeletal deformations. Neonatal complications such as skull hypoplasia, anuria, and death have also been reported. If pregnancy is detected, Irbesartan/Hydrochlorothiazide should be discontinued as soon as possible. Therefore, women of childbearing potential should be advised about the potential risks and should use effective contraception while on this therapy to prevent unintended pregnancy. Discontinuation is critical upon confirmation of pregnancy.
Caution is advised for individuals with primary aldosteronism (hormonal disorder), patients receiving vigorous diuretic therapy, patients with kidney disease (including transplant recipients), patients with heart disease, and diabetic patients.
This medicine may cause drowsiness, which could impair the ability to drive or operate machinery.
Alcohol consumption should be avoided while taking this medication.

How it Works (Mechanism of Action)

Irbesartan is an Angiotensin II Receptor Blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting its vasoconstrictive and aldosterone-secreting effects. Hydrochlorothiazide is a thiazide diuretic that increases the excretion of sodium, chloride, and water by inhibiting sodium reabsorption in the distal convoluted tubule, thereby reducing blood volume and peripheral vascular resistance.